{"id":"https://openalex.org/W7203474584","doi":"https://doi.org/10.1158/1078-0432.c.8653752","title":"Data from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC","display_name":"Data from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC","publication_year":2026,"publication_date":"2026-08-14","ids":{"openalex":"https://openalex.org/W7203474584","doi":"https://doi.org/10.1158/1078-0432.c.8653752"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.8653752","doi":"https://doi.org/10.1158/1078-0432.c.8653752","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.8653752","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.c.8653752","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5062492688","display_name":"Jing Zeng","orcid":"https://orcid.org/0000-0001-7388-8926","observed_orcids":["https://orcid.org/0000-0001-7388-8926"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jing Zeng","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7388-8926","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050248754","display_name":"Sunan Cui","orcid":"https://orcid.org/0000-0002-8846-9449","observed_orcids":["https://orcid.org/0000-0002-8846-9449"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sunan Cui","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8846-9449","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073513316","display_name":"Daniel S. Hippe","orcid":"https://orcid.org/0000-0003-2427-4404","observed_orcids":["https://orcid.org/0000-0003-2427-4404"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel S. Hippe","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2427-4404","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075420800","display_name":"Jie Ying Fu","orcid":"https://orcid.org/0000-0002-5489-2732","observed_orcids":["https://orcid.org/0000-0002-5489-2732"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jie Fu","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5489-2732","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102904201","display_name":"Faisal Yaseen","orcid":"https://orcid.org/0000-0003-4092-0795","observed_orcids":["https://orcid.org/0000-0003-4092-0795"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Faisal Yaseen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4092-0795","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033029643","display_name":"Yulun He","orcid":"https://orcid.org/0000-0001-6258-4986","observed_orcids":["https://orcid.org/0000-0001-6258-4986"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yulun He","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6258-4986","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036277956","display_name":"John Kang","orcid":"https://orcid.org/0000-0003-3915-8350","observed_orcids":["https://orcid.org/0000-0003-3915-8350"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John Kang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3915-8350","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072499473","display_name":"Clemens Grassberger","orcid":"https://orcid.org/0000-0002-4425-4489","observed_orcids":["https://orcid.org/0000-0002-4425-4489"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Clemens Grassberger","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-4425-4489","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090508593","display_name":"Hubert J. Vesselle","orcid":"https://orcid.org/0000-0002-5660-1580","observed_orcids":["https://orcid.org/0000-0002-5660-1580"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hubert J. Vesselle","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5660-1580","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073998569","display_name":"Paul E. Kinahan","orcid":"https://orcid.org/0000-0001-6461-3306","observed_orcids":["https://orcid.org/0000-0001-6461-3306"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul E. Kinahan","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6461-3306","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063427877","display_name":"Keith D. Eaton","orcid":"https://orcid.org/0000-0001-5025-2001","observed_orcids":["https://orcid.org/0000-0001-5025-2001"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Keith D. Eaton","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5025-2001","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058265665","display_name":"Christina S. Baik","orcid":"https://orcid.org/0009-0007-0822-9060","observed_orcids":["https://orcid.org/0009-0007-0822-9060"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christina S. Baik","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0007-0822-9060","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091168604","display_name":"Rafael Santana-D\u00e1vila","orcid":"https://orcid.org/0000-0001-5051-1755","observed_orcids":["https://orcid.org/0000-0001-5051-1755"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rafael Santana-Davila","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5051-1755","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065928902","display_name":"Sylvia M. Lee","orcid":"https://orcid.org/0000-0002-7425-2230","observed_orcids":["https://orcid.org/0000-0002-7425-2230"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sylvia Lee","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7425-2230","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035062387","display_name":"Ramesh Rengan","orcid":"https://orcid.org/0000-0001-5379-536X","observed_orcids":["https://orcid.org/0000-0001-5379-536X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ramesh Rengan","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5379-536X","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5080374314","display_name":"Stephen R. Bowen","orcid":"https://orcid.org/0000-0001-7581-770X","observed_orcids":["https://orcid.org/0000-0001-7581-770X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stephen R. Bowen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7581-770X","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.9761000275611877,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.9761000275611877,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10358","display_name":"Advanced Radiotherapy Techniques","score":0.020899999886751175,"subfield":{"id":"https://openalex.org/subfields/3108","display_name":"Radiation"},"field":{"id":"https://openalex.org/fields/31","display_name":"Physics and Astronomy"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10307","display_name":"Head and Neck Cancer Studies","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2733","display_name":"Otorhinolaryngology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9279999732971191},{"id":"https://openalex.org/keywords/inoperable-lung-cancer","display_name":"inoperable lung cancer","score":0.878000020980835},{"id":"https://openalex.org/keywords/fdg-pet-ct","display_name":"FDG PET/CT","score":0.7749999761581421},{"id":"https://openalex.org/keywords/spect-ct","display_name":"SPECT/CT","score":0.7279999852180481},{"id":"https://openalex.org/keywords/chemoradiotherapy","display_name":"chemoradiotherapy","score":0.7419999837875366},{"id":"https://openalex.org/keywords/radiotherapy-boost","display_name":"boost radiotherapy","score":0.3449999988079071},{"id":"https://openalex.org/keywords/treatment-failure-patterns","display_name":"treatment failure patterns","score":0.6370000243186951},{"id":"https://openalex.org/keywords/locoregional-progression","display_name":"locoregional progression","score":0.8640000224113464},{"id":"https://openalex.org/keywords/distant-metastasis","display_name":"distant metastasis","score":0.9629999995231628},{"id":"https://openalex.org/keywords/risk-stratification","display_name":"risk stratification","score":0.656000018119812},{"id":"https://openalex.org/keywords/radiation-dosimetry","display_name":"radiation dosimetry","score":0.625},{"id":"https://openalex.org/keywords/esophagitis","display_name":"esophagitis","score":0.7730000019073486},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6539999842643738},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9490000009536743}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9124000072479248},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6861000061035156},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6097000241279602},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5806000232696533},{"id":"https://openalex.org/C509974204","wikidata":"https://www.wikidata.org/wiki/Q180507","display_name":"Radiation therapy","level":2,"score":0.5746999979019165},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.5101000070571899},{"id":"https://openalex.org/C88879693","wikidata":"https://www.wikidata.org/wiki/Q217690","display_name":"Cumulative incidence","level":3,"score":0.5077999830245972},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.4900999963283539},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.4334999918937683},{"id":"https://openalex.org/C146357865","wikidata":"https://www.wikidata.org/wiki/Q1123245","display_name":"Stage (stratigraphy)","level":2,"score":0.40869998931884766},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.4025999903678894},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.38370001316070557},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.37689998745918274},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.37049999833106995},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.36910000443458557},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.34439998865127563},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.34200000762939453},{"id":"https://openalex.org/C2778424827","wikidata":"https://www.wikidata.org/wiki/Q5090613","display_name":"Chemoradiotherapy","level":3,"score":0.3154999911785126},{"id":"https://openalex.org/C155806632","wikidata":"https://www.wikidata.org/wiki/Q5299253","display_name":"Dose fractionation","level":3,"score":0.31150001287460327},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.3059000074863434},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.2994999885559082},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.28859999775886536},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.28130000829696655},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.2705000042915344},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.2703000009059906},{"id":"https://openalex.org/C2779709957","wikidata":"https://www.wikidata.org/wiki/Q17093208","display_name":"Median follow-up","level":3,"score":0.26429998874664307},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.2583000063896179}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.c.8653752","doi":"https://doi.org/10.1158/1078-0432.c.8653752","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.8653752","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.8653752","doi":"https://doi.org/10.1158/1078-0432.c.8653752","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.8653752","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7162685465","https://openalex.org/W4402906296","https://openalex.org/W2896274549","https://openalex.org/W3131838920","https://openalex.org/W2601818851","https://openalex.org/W4400314586","https://openalex.org/W3217080958","https://openalex.org/W2463521596","https://openalex.org/W4387208096","https://openalex.org/W3208740382"],"abstract_inverted_index":{"Abstract":[0],"Purpose:":[1],"The":[2,159],"nonrandomized":[3],"phase":[4],"II":[5],"trial":[6],"Functional":[7],"Lung":[8],"Avoidance":[9],"and":[10,30,45,50,73,118,129,141,187,197,210,242,252,267,275,297,308,316,323,331,381,415,449,475,488,496,512],"Response-adaptive":[11],"Escalation":[12],"Radiation":[13],"Therapy":[14],"(FLARE-RT)":[15],"tested":[16],"personalized":[17],"risk-adaptive":[18,513],"radiotherapy":[19,495],"for":[20,232,306,466,515],"unresectable":[21,516],"non\u2013small":[22],"cell":[23],"lung":[24],"cancer":[25],"(NSCLC)":[26],"using":[27],"2[18F]fluoro-2-deoxy-D-glucose":[28],"(FDG)-PET/CT":[29],"single-photon":[31],"emission":[32],"computed":[33],"tomography/CT.":[34],"We":[35],"report":[36],"radiation":[37,218,456],"dosimetry,":[38],"mature":[39],"outcomes,":[40],"adverse":[41,229],"events,":[42],"failure":[43,151,416],"patterns,":[44],"risk":[46,227,485],"stratification":[47],"models.":[48],"Patients":[49,76,88],"Methods:":[51],"Forty-nine":[52],"patients":[53,460],"with":[54,77,89,139,166,345,364,392,410,426,437,451,464,482],"American":[55],"Joint":[56],"Committee":[57],"on":[58,472,477],"Cancer":[59],"version":[60],"7":[61],"stage":[62],"IIB\u2013IIIB":[63],"NSCLC":[64],"enrolled":[65],"in":[66,85,220,292,395,458,506],"FLARE-RT":[67,432],"(NCT02773238)":[68],"from":[69,94],"2016":[70],"to":[71,97,99,105,423,440],"2021":[72],"initiated":[74],"chemoradiation.":[75],"week":[78],"3":[79],"FDG-PET":[80,339,474,479],"response":[81],"received":[82,91,379],"60":[83],"Gy":[84,107,444],"30":[86],"fractions.":[87],"nonresponse":[90],"concomitant":[92],"boosts":[93,219,457],"weeks":[95],"4":[96],"6":[98],"residual":[100],"metabolic":[101],"disease":[102,176,468],"of":[103,149,228,294,302,486,501,509],"74":[104],"90":[106],"total":[108,340],"guided":[109],"by":[110],"FDG":[111],"uptake.":[112],"Overall":[113],"survival":[114,120],"(OS;":[115],"primary":[116,300],"endpoint)":[117],"progression-free":[119],"(PFS)":[121],"were":[122,135,153,201,408,419,461],"estimated":[123,136],"via":[124,137],"Kaplan\u2013Meier.":[125],"Locoregional":[126],"progression":[127,143],"(LRP)":[128],"distant":[130],"metastasis":[131],"(DM)":[132],"cumulative":[133],"incidence":[134,305],"Aalen\u2013Johansen,":[138],"death":[140],"alternative":[142],"patterns":[144,417],"as":[145],"competing":[146],"risks.":[147],"Predictors":[148],"treatment":[150],"modes":[152],"identified":[154],"through":[155],"Fine\u2013Gray":[156],"regression.":[157],"Results:":[158],"median":[160,239,258,281],"patient":[161],"age":[162],"was":[163,245,260,270,283,298,311,326,480],"63.2":[164],"years,":[165],"predominantly":[167],"adenocarcinoma":[168],"histology":[169],"(n":[170,177,183,191,206,213],"=":[171,178,184,192,207,214,351,367,373,390,402],"30,":[172],"61.2%),":[173],"N2":[174],"nodal":[175],"31,":[179,193],"63.3%),":[180],"smoking":[181],"history":[182],"41,":[185],"83.6%),":[186],"carboplatin\u2013paclitaxel":[188],"chemotherapy":[189],"regimen":[190],"63.3%).":[194],"Target":[195],"volumes":[196],"normal":[198],"tissue":[199],"dosimetry":[200],"similar":[202,439],"between":[203],"PET":[204,211],"responders":[205],"33,":[208],"67.3%)":[209],"nonresponders":[212,222],"16,":[215],"32.7%);":[216],"PET-guided":[217],"select":[221,459],"did":[223],"not":[224,420],"increase":[225],"the":[226,299],"events":[230],"except":[231],"grade":[233],"2":[234],"esophagitis.":[235],"At":[236],"52.3":[237],"months":[238,262,285],"follow-up,":[240],"1-":[241,307,322],"2-year":[243,309,324],"OS":[244,259,438],"81.6%":[246],"[95%":[247],"confidence":[248],"interval":[249],"(CI),":[250],"71.5%\u201393.2%]":[251],"54.2%":[253],"(95%":[254,263,272,277,286,313,318,328,333,353,369],"CI,":[255,264,273,278,287,314,319,329,334,354,370],"41.8%\u201370.4%),":[256],"respectively;":[257,280,321],"29.1":[261],"17.3\u2013NA).":[265],"One-":[266],"two-year":[268],"PFS":[269,282],"53.1%":[271],"40.9%\u201369%)":[274],"40.5%":[276],"28.8%\u201357.0%),":[279],"12.3":[284],"9.2\u2013not":[288],"reached).":[289],"DM":[290,325,365,385],"occurred":[291],"18":[293],"31":[295],"cases":[296],"mode":[301],"failure.":[303],"Cumulative":[304],"LRP":[310,347,397,487],"12.2%":[312],"4.9%\u201323.2%)":[315],"18.5%":[317],"9.0%\u201330.6%),":[320],"34.7%":[327],"21.7%\u201348.1%)":[330],"43.1%":[332],"28.9%\u201356.5%),":[335],"respectively.":[336],"Higher":[337],"pre-RT":[338],"lesion":[341],"glycolysis":[342],"(TLG)":[343],"correlated":[344,363],"increased":[346],"[hazard":[348],"ratio":[349],"(HR)":[350],"1.87":[352],"1.41\u20132.49),":[355],"P":[356,372,389,401],"<":[357],"0.001],":[358],"whereas":[359],"higher":[360],"mid-RT":[361],"TLG":[362,471],"[HR":[366],"1.52":[368],"1.05\u20132.21),":[371],"0.03].":[374],"Of":[375,404],"49":[376,405],"patients,":[377,406],"25":[378],"durvalumab":[380],"exhibited":[382],"lower":[383],"1-year":[384,396],"(20%":[386,398],"vs.":[387,399],"54.2%,":[388],"0.04)":[391],"no":[393],"difference":[394],"4.2%,":[400],"0.27).":[403],"26":[407],"treated":[409,425],"proton":[411],"radiotherapy,":[412],"yielding":[413],"outcomes":[414],"that":[418],"different":[421],"compared":[422],"those":[424],"photon":[427],"therapy.":[428],"Conclusions:":[429],"Biological":[430],"image-guided":[431],"achieved":[433],"durable":[434],"locoregional":[435],"control":[436],"RTOG":[441],"0617":[442],"(60":[443],"arm)/RTOG":[445],"1106":[446],"(adaptive":[447],"arm)":[448],"comparable":[450],"PACIFIC":[452],"(durvalumab":[453],"arm).":[454],"Risk-adaptive":[455],"well":[462],"tolerated":[463],"potential":[465],"improved":[467],"control.":[469],"Elevated":[470],"baseline":[473],"residually":[476],"mid-treatment":[478],"associated":[481],"a":[483],"greater":[484],"DM,":[489],"respectively,":[490],"which":[491],"may":[492],"refine":[493],"selective":[494],"systemic":[497],"therapy":[498,514],"intensification.":[499],"Validation":[500],"these":[502],"findings":[503],"is":[504],"warranted":[505],"next-generation":[507],"trials":[508],"imaging":[510],"biomarker-guided":[511],"NSCLC.":[517]},"counts_by_year":[],"updated_date":"2026-10-28T10:33:24.094632","created_date":"2026-08-15T00:00:00"}